AN OVERVIEW OF MUCORMYCOSIS

Authors

  • SELVA PREETHI SAMUNDI Department of Pharmacology, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamil Nadu, India.
  • SARAVANAKUMAR PARAMESWARAN Department of Pharmacology, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamil Nadu, India.
  • MANIMEKALAI PICHAIVEL Department of Pharmacology, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamil Nadu, India.
  • MURUGANANTHAN GOPAL Department of Pharmacognosy, Swamy Vivekananda College of Pharmacy, Elayampalayam, Namakkal, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ijhs.2022.v10i1.45110

Keywords:

Amphotericin B, Angioinvasive infection, Mucormycosis, Zygomycosis

Abstract

Mucormycosis is an angioinvasive infection caused by Zygomycosis in the order of Mucorales. It is mainly affected in immunocompromised individuals followed by risk factors such as diabetes mellitus, stem cell transplantation, organ transplantation, hematological malignancy, and more intake of steroids. Rhino-orbito-cerebral mucormycosis, pulmonary mucormycosis, cutaneous mucormycosis, gastrointestinal mucormycosis, and disseminated mucormycosis are the most common types. Moreover, it can be diagnosed to overcome this infection using the following methods such as histopathology cultures, computed axial tomography, and resonance imaging. Moreover, it can be treated with amphotericin B, the first-line drug, and posaconazole and isavuconazole are also used. The in vitro studies reveal the antifungal drugs which show the best activity against mucormycosis. The main aim of this review shows the detailed study of mucormycosis and the outcome of this infection.

References

Suganya R, Malathi N, Karthikeyan V, Janagaraj VD. Mucormycosis: A brief review. J Pure Appl Microbiol 2019;13:161-5.

Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms 2021;9:523.

Chander J, Kaur M, Singla N, Punia R, Singhal SK, Attri AK, et al. Mucormycosis: Battle with the deadly enemy over a five-year period in India. J Fungi 2018;4:46.

Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146.

Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi 2020;6:265.

Binder U, Maurer E, Lass‐Flörl C. Mucormycosis-from the pathogens to the disease. Clin Microbiol Infect 2014;20:60-6.

Singh S, Pal N, Chander J, Sardana R, Mahajan B, Joseph N, et al. Mucormycosis caused by Syncephalastrum spp.: Clinical profile, molecular characterization, antifungal susceptibility and review of literature. Clin Infect Pract 2021;11:100074.

Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature. Mycopathologia 2021;186:289-98.

Cox GM, Kauffman C, Thorner A. Mucormycosis (zygomycosis). Trauma 2011;34:36.

Spellberg B, Edwards J Jr., Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556-69.

Bouza E, Munoz P, Guinea J. Mucormycosis: An emerging disease? Clin Microbiol Infect 2006;12:7-23.

Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus,-Mucor, and-Lichtheimia species. Clin Microbiol Rev 2011;24:411-45.

Martínez-Herrera E, Frías-De-León MG, Julián-Castrejón A, Cruz-Benítez L, Xicohtencatl-Cortes J, Hernández-Castro R. Rhino-orbital mucormycosis due to Apophysomyces ossiformis in a patient with diabetes mellitus: A case report. BMC Infect Dis 2020;20:614.

Therakathu J, Prabhu S, Irodi A, Sudhakar SV, Yadav VK, Rupa V. Imaging features of rhinocerebral mucormycosis: A study of 43 patients. Egypt J Radiol Nucl Med 2018;49:447-52.

Prabhu R, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004;10:31-47.

Ino K, Nakase K, Nakamura A, Nakamori Y, Sugawara Y, Miyazaki K, et al. Management of pulmonary mucormycosis based on a polymerase chain reaction (PCR) diagnosis in patients with hematologic malignancies: A report of four cases. Intern Med 2017;56:707-11.

Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: Results of medical and surgical therapy. Ann Thorac Surg 1994;57:1044-50.

Feng J, Sun X. Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome. Infection 2018;46:503-12.

Spellberg B. Gastrointestinal mucormycosis: An evolving disease. Gastroenterol Hepatol 2012;8:140-2.

Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi 2019;5:26.

Sarrami AH, Setareh M, Izadinejad M, Afshar-Moghaddam N, Baradaran-Mahdavi MM, Meidani M. Fatal disseminated mucormycosis in an immunocompotent patient: A case report and literature review. Int J Prev Med 2013;4:1468-71.

Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012;54:S55-60.

Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med Mycol 2018;56:29-43.

Jung J, Kim MY, Lee HJ, Park YS, Lee SO, Choi SH, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect 2015;21:684.e11-8.

Jensen HE, Salonen J, Ekfors TO. The use of immunohistochemistry to improve sensitivity and specificity in the diagnosis of systemic mycoses in patients with haematological malignancies. J Pathol 1997;181:100-5.

Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of mucormycosis. J Fungi 2018;4:90.

Alastruey‐Izquierdo A, Castelli M, Cuesta I, Zaragoza O, Monzón A, Mellado E, et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 2009;15:71-6.

Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE, Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003;51:45-52.

Parthiban K, Gnanaguruvelan S, Janaki C, Sentamilselvi G, Boopalraj J. Rhinocerebral zygomycosis: Rhinozerebrale zygomykose. Mycoses 1998;41:51-3.

Quinio D, Karam A, Leroy JP, Moal MC, Bourbigot B, Masure O, et al. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol 2004;42:177-80.

Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38‐A microdilution method. Mycoses 2005;48:246-50.

Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. In an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002;46:2310-2.

Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51:2587-90.

Barchiesi F, Spreghini E, Santinelli A, Fothergill AW, Pisa E, Giannini D, et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother 2007;51:73-7.

Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002;46:1581-2.

Van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-5.

Page RL, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: Case report and review of the literature. Pharmacotherapy 2007;27:290-8.

Stark D, Milliken S, Marriott D, Harkness J. Rhizopus microsporus var. rhizopodiformis sinus-orbital zygomycosis in an immunosuppressed patient: Successful treatment with posaconazole after a complicated clinical course. J Med Microbiol 2007;56:699-701.

Rutar T, Cockerham KP. Periorbital zygomycosis (Mucormycosis) treated with posaconazole. Am J Ophthalmol 2006;142:187-8.

Published

22-07-2022

How to Cite

SAMUNDI, S. P., PARAMESWARAN, S., PICHAIVEL, M., & GOPAL, M. (2022). AN OVERVIEW OF MUCORMYCOSIS. Innovare Journal of Health Sciences, 10(1), 1–7. https://doi.org/10.22159/ijhs.2022.v10i1.45110

Issue

Section

Review Article(s)